Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595127 · ClinicalTrials.gov registry record · NA
Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine
A NA study of Fanconi Anemia, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00595127: Completed NA study of Fanconi Anemia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00595127 is a NA study of Fanconi Anemia that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00595127, a NA study of Fanconi Anemia, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to: (1) determine if the combination of low dose total body irradiation, low dose cyclophosphamide and the addition of fludarabine, and a serum to suppress the immune system can allow selected stem cells to take and grow; (2) determine if selected stem cells from the blood or marrow can take and not cause graft-versus-host disease (GvHD), and; (3) evaluate the side effects of the combination of low dose radiation and chemotherapy drugs used for these transplants.
Primary Outcome
Number of patients who engrafted
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- RADIATION Total body irradiation (TBI)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2001-06 |
| Est. Completion | 2013-05 |
| Phase | NA |
What the finished NCT00595127 record still lists
NCT00595127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 335-participant average among 15 other Fanconi Anemia trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Fanconi Anemia appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00595127 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00595127 about?
NCT00595127 is a clinical study titled "Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine". The purpose of this research study is to: (1) determine if the combination of low dose total body irradiation, low dose cyclophosphamide and the addition of fludarabine, and a serum to suppress the immune system can allow selected stem cells to take and grow; (2) determine if selected stem cells fro...
What is the current status of trial NCT00595127?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2001-06. Estimated completion is 2013-05.
What conditions does trial NCT00595127 study?
This clinical trial studies the following conditions: Fanconi Anemia.
What interventions are being tested in trial NCT00595127?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Total body irradiation (TBI) (RADIATION).
Who is sponsoring clinical trial NCT00595127?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00595127 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fanconi Anemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00595127's enrollment target sits among peer trials
21 11th of 15 higher than 5 of 15 other Fanconi Anemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fanconi Anemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Role of Acetaldehyde in the Development of Oral Cancer
RECRUITING · NA
-
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
ACTIVE NOT RECRUITING · NA
-
Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia
COMPLETED · NA
-
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
RECRUITING · Phase 1
-
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
RECRUITING
-
Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia